BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 10, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ii-Key/HER2/neu cancer vaccine: Additional Phase I data

Additional data from an open-label, Greek Phase I trial in 29 patients showed that 23 patients had vaccine-specific delayed-type hypersensitivity (DTH) responses following immunization with AE37. Median PFS was 18 months...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >